MTRF1

Across TCGA pan-cancer cohorts, MTRF1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MTRF1 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MTRF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTRF1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ESCA, LUAD, and LUSC are the cancer types where MTRF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.102	0.703	<.001	36	view →
LUAD	OS	Median	All	0.171	0.835	<.001	12	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	12	view →
UCEC	DFS	Median	All	1.000	0.629	.028	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.664	.007	5	view →
BRCA	OS	Median	All	0.181	0.579	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MTRF1–ESCA (OS)

Open the ESCA breakdown →